CellSource cuts its way to interim profit, but keeps full-year operating loss forecast
CellSource turned a softer top line into a better interim profit picture. Consolidated revenue for the six months to April slipped 2.5% to JPY 1,775m, but SG&A fell 8.5% and operating profit climbed to JPY 125m from JPY 17m, even as combined blood- and adipose-derived processing cases edged down to 10,114 from 10,303. Management still kept its full-year forecast for a JPY 170m operating loss, saying the year remains one of strategic investment rather than tidy recovery.